Sanofi (SNY) Depreciation and Depletion (2009 - 2026)
Sanofi (SNY) posted Depreciation and Depletion of $367.1 million for Q1 2025, down 77.78% sequentially from $1.7 billion in Q4 2024, and up 3.03% YoY from $356.3 million in Q1 2024.
Sanofi (SNY) Depreciation and Depletion (2009 - 2026) Analysis & Trends
Sanofi (SNY) has 17 years of Depreciation and Depletion data on file, last reported at $367.1 million in Q1 2025.
- Quarterly Depreciation and Depletion rose 3.03% year-over-year to $367.1 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $4.0 billion (changed 0.07% YoY) and the FY2024 annual result came in at $1.2 billion, down 3.51% from the prior year.
- Depreciation and Depletion fell to $367.1 million in Q1 2025 per SNY's latest filing, from $1.7 billion in the prior quarter.
- The five-year high for Depreciation and Depletion was $1.7 billion in Q4 2021, with the low at $356.3 million in Q1 2024.
- Average Depreciation and Depletion over 5 years is $946.6 million, with a median of $418.6 million recorded in 2021.
- Year-over-year, Depreciation and Depletion gained 3.31% in 2021 and decreased 10.28% in 2024.
- Sanofi's Depreciation and Depletion stood at $1.7 billion in 2021, then retreated by 3.65% to $1.6 billion in 2022, then advanced by 0.28% to $1.6 billion in 2023, then advanced by 1.75% to $1.7 billion in 2024, then plunged by 77.78% to $367.1 million in 2025.
- Business Quant data shows SNY's Depreciation and Depletion at $367.1 million in Q1 2025, $1.7 billion in Q4 2024, and $356.3 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Sanofi | - | - | 9.49 Bn | 403.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 403.91 Mn |
| Mar 31, 2026 | 403.91 Mn |
| Dec 31, 2025 | 1.67 Bn |
| Dec 31, 2025 | 1.67 Bn |
| Mar 31, 2025 | 367.11 Mn |
| Mar 31, 2025 | 367.11 Mn |
| Dec 31, 2024 | 1.65 Bn |
| Dec 31, 2024 | 1.65 Bn |
| Mar 31, 2024 | 356.33 Mn |
| Mar 31, 2024 | 356.33 Mn |
| Dec 31, 2023 | 1.62 Bn |
| Dec 31, 2023 | 1.62 Bn |
| Mar 31, 2023 | 397.14 Mn |
| Mar 31, 2023 | 397.14 Mn |
| Dec 31, 2022 | 1.62 Bn |
| Dec 31, 2022 | 1.62 Bn |
| Mar 31, 2022 | 405.16 Mn |
| Mar 31, 2022 | 405.16 Mn |
| Dec 31, 2021 | 1.68 Bn |
| Dec 31, 2021 | 1.68 Bn |